Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares saw unusually-strong trading volume on Friday . Approximately 607,787 shares traded hands during mid-day trading, an increase of 2% from the previous session’s volume of 595,285 shares.The stock last traded at $3.59 and had previously closed at $3.38.

Several analysts have issued reports on ANTH shares. HC Wainwright started coverage on shares of Anthera Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $10.00 price target on the stock. Jefferies Group restated a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 9th. Piper Jaffray Cos. decreased their price target on shares of Anthera Pharmaceuticals from $14.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, March 11th. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research report on Friday, March 11th. Finally, FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $9.58.

The stock has a 50 day moving average of $3.37 and a 200-day moving average of $3.53. The stock’s market cap is $156.16 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.01. On average, equities research analysts anticipate that Anthera Pharmaceuticals Inc. will post ($1.25) EPS for the current fiscal year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.